A New Type of Human Well-being Drug Is Coming! Develop The Tens of Billions of Opioid Painkillers Market

On April 25, Renfu Pharma announced that the clinical application for the Class 1 new drug RFUS-144 injection of its holding subsidiary Yichang Renfu was accepted by CDE. The drug is a selective opioid receptor agonist. According to data from Minet.com, in 2020, the sales of terminal opioid painkillers in Chinese public medical institutions exceeded 12.6 billion yuan.

RFUS-144 injection is intended to be clinically used for the treatment of pain and pruritus. It is a selective opioid receptor agonist, and there is currently no similar product on the market in China. Up to now, the accumulated investment of Yichang Renfu project is about 11 million yuan.

According to data from Minet.com, in 2020, the sales of terminal opioid painkillers in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 12.6 billion yuan, and in the first half of 2021, its sales were close to 6.7 billion yuan, a year-on-year increase of 16.26%. The sales of three varieties including dezocine, butorphanol and oxycodone ranked among the top three.

Renfu Medicine is a national designated R&D and production enterprise for narcotic drugs, and is currently in a relatively leading position in the domestic anesthesia and analgesia field. RFUS-144 injection is Renfu Medicine's first Class 1 new drug to apply for clinical application this year.

In addition to Class 1 new drugs, Renfu Medicine has also made a series of progress in the field of improved new drugs this year, including the application for listing of isoflurane injection, paracetamol and oxycodone sustained-release tablets, dexmedetomidine hydrochloride nasal spray, and dexmedetomidine hydrochloride nasal spray. Three new drugs, including Detomidine Transdermal Patch (II), were approved for clinical use.